Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ShotCAR-Her2
- Development stage
- Preclinical
- Lead developer
- Hauul Bio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ShotCAR-Her2 is an investigational chimeric antigen receptor (CAR) cell therapy developed by Hauul Bio for the treatment of HER2-positive solid tumors. The therapy utilizes the company's proprietary ShotCAR platform to engineer cells that specifically target the Human Epidermal Growth Factor Receptor 2 (HER2), a protein frequently overexpressed in various malignancies including breast, lung, and colorectal cancers. Currently in the preclinical stage, ShotCAR-Her2 is being evaluated for its potential in treating indications such as triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). The ShotCAR technology is designed to enhance the efficacy and persistence of CAR cells within the challenging microenvironment of solid tumors, aiming to overcome common barriers to cell therapy in non-hematological cancers.
- Other names
- ShotCAR-HER2ShotCAR-HER-2ShotCAR-HER 2
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on ShotCAR-Her2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ShotCAR-Her2.